Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference [Canadian Business Journal (Canada)]
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre